Sorrento Therapeutics (SRNE)
(Delayed Data from OTC)
$0.02 USD
0.00 (7.14%)
Updated May 3, 2024 03:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SRNE 0.02 0.00(7.14%)
Will SRNE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SRNE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRNE
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
SRNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sorrento Therapeutics (SRNE) Loses -77.24% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Is AMN Healthcare Services (AMN) Stock Outpacing Its Medical Peers This Year?
ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates
Other News for SRNE
Three new option listings on April 15th